Chronic Lymphocytic Leukemia Update, Issue 1, 2019 — Part 2: Our
most recent one-on-one interview with Dr Mato featuring emerging
research and cases from his practice:
Emerging data and recent advances in the management of CLL
(00:00)
Perspective on the role of MRD assessment in therapeutic
decision-making (03:13)
Duration of therapy for patients with CLL; integration of
venetoclax into the treatment algorithm (05:44)
Available data with the addition of rituximab or obinutuzumab
to novel therapies (08:07)
Selection of patients with CLL for treatment with FCR
(fludarabine/cyclophosphamide/rituximab) (11:44)
Novel combination approaches to limiting the duration of
therapy for patients with CLL (13:36)
Spectrum and incidence of toxicities with ibrutinib/venetoclax
compared to either agent alone (15:41)
Therapeutic options for patients with CLL in the first-line
setting (17:55)
Safety profile and quality of life with venetoclax versus
ibrutinib (19:37)
Frequency of and reasons for discontinuation of therapy with
ibrutinib (22:37)
Left atrial abnormality as a predictor of ibrutinib-associated
atrial fibrillation in patients with CLL (24:48)
Real-world outcomes and management strategies for patients with
venetoclax-treated CLL in the United States (27:04)
Role of chemoimmunotherapy in the management of
relapsed/refractory CLL (31:24)
Clinical experience with and management of ibrutinib-associated
adverse events (33:21)
Investigation of ibrutinib in combination with CAR T-cell
therapy for CLL (37:37)
Case: A woman in her mid-70s with del(17p) CLL
and no IGHV mutation experiences arthralgia and hypertension during
second-line therapy with ibrutinib (40:53)
Incidence and management of hypertension associated with
ibrutinib (42:52)
Dose reductions of ibrutinib to mitigate side effects; effect
on efficacy (46:21)
Case: A man in his mid-60s with a history of
hypertension and atrial fibrillation receives acalabrutinib as
first-line therapy for CLL (49:08)
Headaches and hypertension associated with acalabrutinib
(50:20)
Comparative efficacy and spectrum of kinase activity with
ibrutinib, acalabrutinib and zanubrutinib (52:38)
Activity and tolerability of acalabrutinib versus ibrutinib
(54:38)
Case: A woman in her mid-50s with von
Willebrand disease and CLL receives venetoclax after experiencing
disease progression through several lines of therapy (56:58)
Dose adjustments of venetoclax and management of TLS
(1:01:18)
Case: A woman in her late 80s with del(13q)
CLL with IGHV mutation, symptomatic anemia and lymphadenopathy
receives first-line obinutuzumab (1:04:19)
Clinical experience with obinutuzumab-associated
infusion-related reactions (1:06:26)
Choice of first-line therapy for older patients with CLL
(1:08:34)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.